Drug intelligence / Profile preview

GSK3536867

Development stage: Phase 1
Lead developer: GSK
Modality: Vaccines & Immunotherapeutics

Overview

**GSK3536867** is a bivalent conjugate vaccine candidate developed by GSK for the prevention of Salmonella infections, specifically targeting typhoid and paratyphoid A. It aims to induce immune responses against both serotypes through conjugation technology, which enhances immunogenicity of bacterial polysaccharides. The program reached Phase I clinical trials but was discontinued as part of GSK's pipeline adjustments to focus on higher-priority assets.[2][9][11][14]

Other names: bivalent Typhoid and Paratyphoid A conjugate vaccine

Targets

CD209 (Dendritic cell-specific intercellular adhesion Molecule-3-Grabbing non-integrin)Paratyphi A antigen (Salmonella Paratyphi A antigen)Salmonella Paratyphi A O-antigen-specific B-cell receptor (SPA O-antigen BCR)Vi antigen (Vi capsular polysaccharide)Vi polysaccharide-specific B-cell receptor

Beyond the preview

Go deeper on GSK3536867.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on GSK3536867.